Outlook Therapeutics reported a minimal revenue of $9 thousand for the third fiscal quarter of 2026, significantly trailing expectations as the company transitions toward its first U.S. commercial rollout. Following the July 2024 FDA approval of LYTENAVA™ for wet AMD, management is focused on building a specialized commercial infrastructure and expects a U.S. launch by the end of calendar 2026. The company recently fortified its balance sheet with a $51.1 million net public offering completed in August to fund these commercialization efforts.
Key Highlights
- Revenue of $9 thousand fell well short of the $0.97 million consensus estimate, reflecting the current pre-launch status in the domestic market.
- Adjusted net loss of $10.9 million, or $0.09 per share, matched analyst expectations and improved from a $15.8 million adjusted loss in the prior year period.
- Pro forma cash liquidity increased to approximately $62.3 million when accounting for the $51.1 million in net proceeds from the August 2026 public offering and the $11.2 million cash balance at quarter-end.